Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Suplatast tosilate

Suplatast tosilate

pharmaceutical raw materials
Suplatast tosilate structure

Suplatast tosilate 

structure
  • CAS No:

    94055-76-2

  • Formula:

    C16H26NO4S.C7H7O3S

  • Chemical Name:

    Suplatast tosilate

  • Synonyms:

    Sulfonium,[3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-,4-methylbenzenesulfonate (1:1);Sulfonium,[3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-,salt with 4-methylbenzenesulfonic acid (1:1);Suplatast tosilate;Suplatast tosylate;IPD 1151T;[2-[4-(3-Ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate;(±)-[2-[4-(3-Ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate;160114-29-4;1776086-79-3

  • Categories:

    Active Pharmaceutical Ingredients  >  Respiratory Drugs

Description

Suplatast tosilate(IPD 1151T) is a Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production. IC50 value:Target: Th2 cytokine inhibitorSuplatast Tosilate acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Suplatast Tosilate(IPD 1151T) exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.

Suplatast tosilate Basic Attributes

499.64062

499.169830

DTXSID9045003

Characteristics

134

white to off-white

70-73 °C

DMSO: >20mg/mL

Store at RT

LD50 in male, female mice, male, female rats (mg/kg): 81, 96, 96, 93 i.v.; in mice, rats (g/kg): >12.5, >10 orally (Yamashita)

Safety Information

NONH for all modes of transport

3

WR7906000

P201, P202, P281, P308+P313, P405, P501

H361

|Warning|H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]|P201, P202, P281, P308+P313, P405, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Drug Information

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)|Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)

(2-(4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl)ethyl)dimethylsulfonium p-toluenesulfonate

Suplatast tosilate Use and Manufacturing

Methods of Manufacturing

Add 5.0 g (15.95 mmol) of intermediate 3 to the reaction flask at 20~30 °C.5.94 g of p-toluenesulfonic acid methyl ester (31.91 mmol), stir to 50-60 ° C, react for 20-24 h, add 10 mL of acetone for 30 minutes, filter, filter cake and add 20 mL of acetone to recrystallize to obtain metformin. 6.8 g, yield 85.0

Uses

Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.

Computed Properties

Molecular Weight:499.6
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:10
Exact Mass:499.16984474
Monoisotopic Mass:499.16984474
Topological Polar Surface Area:134
Heavy Atom Count:33
Complexity:500
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Not yet clear

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • Zein BIOTECHNOLOGY Co., Ltd.

    China China
    Active

Recommended Suppliers of Suplatast tosilate

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.